Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID‐19: A phase 2a, open‐label, single‐dose escalation study

To assess viral clearance, pharmacokinetics, tolerability and symptom evolution following ensovibep administration in symptomatic COVID‐19 outpatients.

[1]  M. Stumpp.  Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants , 2021, bioRxiv.

[2]  Janet Diaz,et al.  A clinical case definition of post-COVID-19 condition by a Delphi consensus , 2021, The Lancet Infectious Diseases.

[3]  P. Pang,et al.  Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. , 2021, The New England journal of medicine.

[4]  John D. Davis,et al.  REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 , 2021, The New England journal of medicine.

[5]  D. Skovronsky,et al.  Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 , 2021, The New England journal of medicine.

[6]  Santosh Shenoy.  SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons learned one year into the pandemic: A systematic review , 2021, World journal of critical care medicine.

[7]  G. Biele,et al.  Estimating infectiousness throughout SARS-CoV-2 infection course , 2021, Science.

[8]  K. Neuzil.  Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control. , 2021, The New England journal of medicine.

[9]  D. Fremont,et al.  Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies , 2021, Nature Medicine.

[10]  H. Ullum,et al.  Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients , 2021, Scientific Reports.

[11]  D. Skovronsky,et al.  Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[12]  D. Broering,et al.  Effect of COVID-19 on liver abnormalities: a systematic review and meta‐analysis , 2020, Scientific Reports.

[13]  E. Vieira,et al.  COVID-19 gastrointestinal manifestations: a systematic review , 2020, Revista da Sociedade Brasileira de Medicina Tropical.

[14]  S. Kent,et al.  Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies , 2020, Nature Microbiology.

[15]  R. Fiorotto,et al.  Abnormal Liver Function Tests in Patients With COVID‐19: Relevance and Potential Pathogenesis , 2020, Hepatology.

[16]  S. Lindstrom,et al.  US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Emerging infectious diseases.

[17]  Francisco J. López,et al.  Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration , 2018, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[18]  Arthur Christopoulos,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview , 2017, British journal of pharmacology.

[19]  A. Tolcher,et al.  Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin , 2011, Clinical Cancer Research.

[20]  Paulette Gallant,et al.  Evaluation of a Visual Infusion Phlebitis Scale for Determining Appropriate Discontinuation of Peripheral Intravenous Catheters , 2006, Journal of infusion nursing : the official publication of the Infusion Nurses Society.

[21]  R. Rappaport,et al.  Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis , 2005, Virology Journal.

[22]  G. Kärber,et al.  Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche , 1931, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[23]  A. Malik,et al.  Protein transport across the lung epithelial barrier. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[24]  C. Spearman,et al.  The method of 'right and wrong cases' ('constant stimuli') without Gauss's formulae , 1908 .